Niagen Bioscience, Inc. Common Stock NAGE Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 64.3%+2.4pp | 61.8%+1.1pp | 60.8%— | —— | |
| Operating margin | 12.6%+4.8pp | 7.8%+14.5pp | -6.7%— | —— | |
| Net margin | 13.4%+4.8pp | 8.6%+14.6pp | -6%— | —— | |
| Returns | |||||
| Return on equity | 28.3%+5.4pp | 22.9%+40.6pp | -17.7%— | —— | |
| Return on invested capital | 167.3%-101pp | 268.6%+349pp | -80.1%— | —— | |
| Efficiency | |||||
| Asset turnover | 1.5×-0.1× | 1.6×+0.1× | 1.5×— | —— | |
| Liquidity | |||||
| Current ratio | 4.9×+1.3× | 3.6×+1.2× | 2.4×-0.2× | 2.6×-0.2× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0.1×0.0× | 0×-0.1× | 0.1×0.0× | |
| Net debt / EBITDA | -3.6×+1.3× | -4.9×— | —— | —— | |
| Per Share | |||||
| Book value per share | $0.90+51.8% | $0.59+55.5% | $0.38-7.7% | $0.41-12.9% | |
| Valuation | |||||
| Market capitalization | $254.07M-74.9% | —— | —— | —— | |
| Price / earnings | 13.6×-43.5× | —— | —— | —— | |
| Price / sales | 2×-6.8× | —— | —— | —— | |
| Price / book | 3.3×-13.6× | —— | —— | —— | |
| EV / EBITDA | 15×-44.1× | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Niagen Bioscience, Inc. Common Stock's profit margins?
- Niagen Bioscience, Inc. Common Stock (NAGE) runs a 64.3% gross margin and a 10.0% operating margin, with a 14.3% net margin.
- Where do Niagen Bioscience, Inc. Common Stock's ratios come from?
- Every ratio is computed from Niagen Bioscience, Inc. Common Stock's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
